Aside Posted on Updated on
A new comprehensive study of all clinical trials in the CT space. They looked at every stem cell trial listed in worldwide registries up to Dec. 31, 2012. Of the 4,749 studies, almost 80% involve improving bone marrow transplantation using hematopoietic (blood-forming) stem cells to treat leukemia and other blood-based cancers — or treating transplant-related conditions. Also presenting new applications for SC therapies and the industry role.
Prof. Bubela, , a lawyer and Associate Professor at University of Alberta School of Public Health, wrote the report with lead author Dr. Matthew D. Li of the Stanford University School of Medicine, and Dr. Harry Atkins, a clinician/researcher at the Ottawa Hospital Research Institute who specializes in stem cell transplantation for the treatment of autoimmune diseases.
“General optimism exist that stem-cell based regenerative strategies will be transformative and there is a rush to use stem cell products in the clinical realm”. As we know the CT space it is still in its growing pains mode and faces structural, commercial and other challenges as the authors emphasize in this piece.
The authors expand, on CT geographically as well as expanding on cell types and use such as the first trial in 2013 on iPSC’s in Japan.
For more please follow the link: The global landscape of stem cell clinical trials